New study investigates blood clot risks in kids with leukemia
NCT ID NCT07071051
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study is for children and young adults (ages 2 to 21.5) with acute lymphoblastic leukemia or lymphoma who are scheduled to receive the chemotherapy drug calaspargase pegol. The goal is to understand how this drug affects the body's ability to form blood clots. Researchers will take blood samples before and after treatment to track any changes in clotting. The study does not test a new treatment but aims to gather important safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.